Home Cart Sign in  
Chemical Structure| 1135695-98-5 Chemical Structure| 1135695-98-5

Structure of Q-VD-OPh
CAS No.: 1135695-98-5

Chemical Structure| 1135695-98-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties, inhibiting caspase 7 with an IC50 of 48 nM and caspases 1, 3, 8, 9, 10, and 12 with IC50s of 25-400 nM. Q-VD-OPh can inhibit HIV infection and cross the blood-brain barrier.

Synonyms: Quinoline-Val-Asp-Difluorophenoxymethylketone

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Q-VD-OPh

CAS No. :1135695-98-5
Formula : C26H25F2N3O6
M.W : 513.49
SMILES Code : O=C(O)C[C@H](NC([C@@H](NC(C1=NC2=CC=CC=C2C=C1)=O)C(C)C)=O)C(COC3=C(F)C=CC=C3F)=O
Synonyms :
Quinoline-Val-Asp-Difluorophenoxymethylketone
MDL No. :MFCD08669741
InChI Key :OOBJCYKITXPCNS-REWPJTCUSA-N
Pubchem ID :24794416

Safety of Q-VD-OPh

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Q-VD-OPh

pyroptosis

Isoform Comparison

Biological Activity

Target
  • Caspase-3

    Caspase-3, IC50:25 nM-400 nM

  • Caspase-8

    Caspase-8, IC50:25 nM-400 nM

  • Caspase-9

    Caspase-9, IC50:25 nM-400 nM

  • Caspase-1

    Caspase-1, IC50:25 nM-400 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MyLa cells 10 μM 4 h Inhibited caspase activity, preventing DT2216-induced apoptosis PMC7364785
Human neutrophils 50 μM 3 days CLON-G treatment significantly extended the in vitro lifespan of neutrophils from less than 1 day to more than 5 days. PMC10336857
Mouse neutrophils 50 μM 3 days CLON-G treatment significantly extended the in vitro lifespan of mouse neutrophils from less than 1 day to more than 5 days. PMC10336857
mouse LSK cells 50 µM 24 h Continuous treatment of mouse LSK cells with Q-VD-OPh strongly protected cells from cytokine deprivation-induced apoptosis. PMC5626392
MDA-MB-231 cells 40 μM 30 min Pretreatment with Q-VD-OPh led to decreased cell death in MDA-MB-231 cells after MNNG treatment, indicating that Q-VD-OPh inhibited caspase-mediated apoptosis. PMC3494550
PARG-null cells 40 μM 30 min Pretreatment with Q-VD-OPh resulted in decreased caspase-3/7/8/9 activity in PARG-null cells after UV treatment, indicating that Q-VD-OPh inhibited caspase activity. PMC3494550
Rat enteric glial cells (EGCs) 0.02 µM, 0.2 µM, 0.5 µM, 1 µM, 2 µM, 10 µM, 25 µM, 50 µM 1 h Q-VD-OPh at concentrations of 50 µM, 25 µM, and 10 µM completely inhibited apoptosis induced by both TcdB alone and TcdB + CKs, while at 2 µM it reduced apoptosis by more than 83%, and at 1 µM it reduced apoptosis by about 60%. PMC9304068
Cos7 cells 450 nM 12 h Q-VD-OPh effectively inhibited the generation of CTF2 but not CTF1. PMC6162258
Mouse splenic dendritic cells 5 µM 4 h Q-VD-OPh significantly increased the survival rate of mouse pDCs after STING activation by inhibiting caspase-3/7 activity. PMC8914948

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice wild-type mice Intraperitoneal injection 20mg/Kg 4 hours prior to infection and 20 hours post infection To evaluate the effect of Q-VD-OPh on hepatocyte apoptosis, results showed that Q-VD-OPh treatment reduced the number of hepatic CSF1R+ CD11c+ cells harboring Py-GFP. PMC6459714
Mice ConA-induced hepatitis model Intraperitoneal injection 20 mg/kg Single injection, lasting 11 hours Q-VD-OPh greatly decreased the number of cleaved-caspase-3-positive cells and significantly reduced hepatolysis, indicating its protective effect on ConA-induced hepatitis. PMC5260888
mouse LSK cell transplantation model ex vivo treatment 50 µM Single treatment, lasting 24 hours Q-VD-OPh-treated mouse LSK cells did not show a significant competitive advantage after transplantation, indicating that transient cell death inhibition is not sufficient to promote improved engraftment. PMC5626392

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.19mL

9.74mL

1.95mL

0.97mL

19.47mL

3.89mL

1.95mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Caserta TM, Smith AN, et al. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003 Aug;8(4):345-52

[2]Caserta TM, Smith AN, et al. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003 Aug;8(4):345-52.

[3]Sanders EJ, Parker E, et al. Retinal ganglion cell survival in development: mechanisms of retinal growth hormone action. Exp Eye Res. 2006 Nov;83(5):1205-14. Epub 2006 Aug 7.

[4]Colak A, Antar V, et al. Q-VD-OPh, a pancaspase inhibitor, reduces trauma-induced apoptosis and improves the recovery of hind-limb function in rats after spinal cord injury. Neurocirugia (Astur). 2009 Dec;20(6):533-40; discussion 540.

[5]Renolleau S, Fau S, et al. Specific caspase inhibitor Q-VD-OPh prevents neonatal stroke in P7 rat: a role for gender. J Neurochem. 2007 Feb;100(4):1062-71. Epub 2006 Dec 12.

[6]Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003 Aug;8(4):345-52. doi: 10.1023/a:1024116916932. PMID: 12815277.

[7]Rohn TT, Kokoulina P, Eaton CR, Poon WW. Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int J Clin Exp Med. 2009 Nov 5;2(4):300-8. PMID: 20057974; PMCID: PMC2802048.

[8]Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest. 2002 Oct;110(8):1083-91. doi: 10.1172/JCI15623. PMID: 12393844; PMCID: PMC150794.

[9]DeBiasi RL, Robinson BA, Sherry B, Bouchard R, Brown RD, Rizeq M, Long C, Tyler KL. Caspase inhibition protects against reovirus-induced myocardial injury in vitro and in vivo. J Virol. 2004 Oct;78(20):11040-50. doi: 10.1128/JVI.78.20.11040-11050.2004. PMID: 15452224; PMCID: PMC521817.

 

Historical Records

Categories